Neuren granted U.S. patent for NNZ-2566 for traumatic brain injury

By E. Janene Geiss

Philadelphia, May 11 - Neuren Pharmaceuticals announced Thursday that its patent application entitled "GPE Analogs and Peptidomimetics" has been issued this week in the United States.

The patent describes Neuren's second pipeline drug, NNZ-2566, a neuroprotective analogue of Glypromate and covers the chemical composition of NNZ-2566 in all formulations, and all uses of the compound, according to a company news release.

The patent also specifically covers therapeutic applications of NNZ-2566 for the treatment of damage to the central nervous system.

Neuren said it now has the exclusive rights to make, sell and use NNZ-2566 in the United States until May 24, 2022.

The U.S. patent gives Neuren a unique position to investigate and commercialize NNZ-2566 as a systemic neuroprotective treatment following acute insults to the central nervous system such as traumatic brain injury, stroke or oxygen deprivation of the brain associated with coronary artery bypass graft surgery, as well as chronic degenerative conditions of the central nervous system such as Alzheimer's and Parkinson's disease.

Neuren said it is currently co-developing NNZ-2566 as a treatment for traumatic brain injury with the U.S. Army's Walter Reed Army Institute of Research.

The issued patent is the parent to the recent patent filing by Neuren based on the results of experiments by the Walter Reed institute showing a reduction in non-convulsive seizures after administration of NNZ-2566.

Non-convulsive seizures are an important predictor of recovery following brain injury. NNZ-2566 is currently undergoing a phase 1 safety and pharmacokinetics trial.

In addition to therapeutic use of NNZ-2566 in acute indications, Neuren said it plans to develop NNZ-2566 as a protective therapeutic in a variety of chronic neurodegenerative diseases.

Neuren is a Sydney, Australia, biotechnology company developing novel therapeutics in the fields of neurotherapy and metabolic disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.